{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:28:56Z","timestamp":1788409736124,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd011108.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000}}],"reference-count":85,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011108.pub3","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T10:26:57Z","timestamp":1628159217000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hydromorphone for cancer pain"],"prefix":"10.1002","volume":"2021","author":[{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department for Anesthesiology and Pain Management; The People's Hospital of Jizhou District, Tianjin; Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Anesthesiology; Beijing Anzhen Hospital, Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guijun","family":"Lu","sequence":"additional","affiliation":[{"name":"Pain Medicine Department; Beijing Tsinghua Changgung Hospital; Bejing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Dou","sequence":"additional","affiliation":[{"name":"Pain Medicine Department; Xuanwu Hospital, Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Knaggs","sequence":"additional","affiliation":[{"name":"School of Pharmacy; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd; The Ingenuity Centre, The University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd; The Ingenuity Centre, The University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Psychiatry and Applied Psychology, School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Pain Medicine Department; Xuanwu Hospital, Capital Medical University; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"e0235461","DOI":"10.1371\/journal.pone.0235461","article-title":"Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial","volume":"15","author":"Banala","year":"2020","journal-title":"PloS One"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Hagen NA Babul N Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain Cancer 1997 79 7 1428 37","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1428::AID-CNCR21>3.0.CO;2-0"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-684X-7-17","article-title":"A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain","volume":"7","author":"Hanna","year":"2008","journal-title":"BMC Palliative Care"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0004|cit4","unstructured":"A study of OROS hydromorphone HCl vs morphine in cancer pain patients clinicaltrials.gov\/ct2\/show\/NCT00410540"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2147\/JPR.S136937","article-title":"A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief)","volume":"10","author":"Inoue","year":"2017","journal-title":"Journal of Pain Research"},{"issue":"6","key":"10.1002\/14651858.CD011108.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jjco\/hyy038","article-title":"A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients","volume":"48","author":"Inoue","year":"2018","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0007|cit7","unstructured":"The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN17751043"},{"issue":"11","key":"10.1002\/14651858.CD011108.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1097\/j.pain.0000000000001957","article-title":"Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial","volume":"161","author":"Ma","year":"2020","journal-title":"Pain"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0009|cit9","unstructured":"Moriarty M McDonald CJ Miller AJ A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain Journal of Clinical Research 1999 2 1 8"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0010|cit10","unstructured":"An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain clinicaltrials.gov\/ct2\/show\/NCT01205126"},{"issue":"8","key":"10.1002\/14651858.CD011108.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jpain.2014.04.008","article-title":"Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study","volume":"15","author":"Yu","year":"2014","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jclinane.2016.08.025","article-title":"Optimal epidural analgesia for patients diagnosed as having gynecologic cancer undergoing interstitial brachytherapy","volume":"35","author":"Amsbaugh","year":"2016","journal-title":"Journal of Clinical Anesthesia"},{"issue":"3","key":"10.1002\/14651858.CD011108.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00520-013-2030-1","article-title":"A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics","volume":"22","author":"Han","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5055\/jom.2012.0122","article-title":"Clinical effectiveness and safety of OROS hydromorphone in breakthrough cancer pain treatment: a multicenter, prospective, open-label study in Korean patients","volume":"8","author":"Lee","year":"2012","journal-title":"Journal of Opioid Management"},{"issue":"9","key":"10.1002\/14651858.CD011108.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00520-007-0368-y","article-title":"Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain","volume":"16","author":"Wirz","year":"2008","journal-title":"Supportive Care Cancer"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpain.2008.09.005","article-title":"Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine","volume":"13","author":"Wirz","year":"2009","journal-title":"European Journal of Pain"},{"issue":"37","key":"10.1002\/14651858.CD011108.pub3-BIB0017|cit17","first-page":"1","article-title":"Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on Open Access mood, opioid adverse effects, and recovery","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Anesthesiology"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0018|cit18","unstructured":"Double-blind, double-dummy, randomised, parallel-arm equivalence [non-inferiority] study comparing hydromorphone hydrochloride extended-release [HHER] capsules to MS Contin tablets, dosed at a ratio of 1:7.5 to relieve pain, in cancer or non-cancer patients with a history of moderate to severe pain www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=682"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0019|cit19","unstructured":"A multicenter, randomized, parallel, controlled clinical study of patient controlled intravenous analgesia with hydromorphone hydrochloride injection and morphine hydrochloride injection for moderate to severe cancer http:\/\/www.chictr.org.cn\/hvshowproject.aspx?id=20839"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0020|cit20","unstructured":"A multicenter clinical trial of hydromorphone PCA versus oxycodone oral titration in the treatment of cancer pain http:\/\/www.chictr.org.cn\/com\/25\/hvshowproject.aspx?id=63054"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0021|cit21","unstructured":"A multicenter clinical trial of hydromorphone hydrochloride in the treatment of cancer breakthrough pain http:\/\/www.chictr.org.cn\/showproj.aspx?proj=22941"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0022|cit22","unstructured":"A multicenter, multinational, randomized, open-label, parallel-group trial to evaluate the safety of fentanyl TAIFUN; treatment after titrated dose administration and the current breakthrough pain treatment for breakthrough pain in cancer patients on maintenance opioid therapy http:\/\/www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=493&EncHid=&modid=&compid=%27,%27493det%27"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0023|cit23","unstructured":"Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain requiring continuous opioid therapy https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2004-005187-24\/SK"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0024|cit24","unstructured":"Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2008-002273-12\/IT"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0025|cit25","unstructured":"DS-7113b extended-release tablet phase III study https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=JapicCTI-142666"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0026|cit26","unstructured":"The safety of fentanyl TAIFUN treatment after titrated dose administration and the current breakthrough pain treatment for breakthrough pain in cancer patients clinicaltrials.gov\/ct2\/show\/NCT00822614"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0027|cit27","unstructured":"Study of opioid rotation versus opioid escalation in patients with moderate to severe cancer pain clinicaltrials.gov\/ct2\/show\/NCT02084355"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0028|cit28","unstructured":"Intravenous vs oral analgesia in cancer patients with severe pain after successful titration clinicaltrials.gov\/ct2\/show\/NCT04243954"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0029|cit29","unstructured":"Effect of opioid infusion rate on abuse liability potential of intravenous hydromorphone for cancer pain clinicaltrials.gov\/ct2\/show\/NCT04296305"},{"issue":"10","key":"10.1002\/14651858.CD011108.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/pon.1122","article-title":"Associated and predictive factors of sleep disturbance in advanced cancer patients","volume":"16","author":"Akechi","year":"2007","journal-title":"Psycho-oncology"},{"issue":"1","key":"10.1002\/14651858.CD011108.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00000542-200101000-00014","article-title":"Pharmacodynamics of orally administered sustained-release hydromorphone in humans","volume":"94","author":"Angst","year":"2001","journal-title":"Anesthesiology"},{"issue":"14","key":"10.1002\/14651858.CD011108.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/00002018-200225140-00004","article-title":"Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study","volume":"25","author":"Bass","year":"2002","journal-title":"Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1533-2500.2009.00342.x","article-title":"A randomized study to demonstrate noninferiority of once-daily OROS\u00ae hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain","volume":"10","author":"Binsfeld","year":"2010","journal-title":"Pain Practice"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0269216310392102","article-title":"Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project","volume":"25","author":"Caraceni","year":"2011","journal-title":"Palliative Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011108.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncology"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012638.pub2","article-title":"Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults","author":"Derry","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/00000542-200210000-00013","article-title":"Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers","volume":"97","author":"Drover","year":"2002","journal-title":"Anesthesiology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD011108.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0039|cit39","first-page":"349","article-title":"Pathogenesis and management of cancer-related insomnia","volume":"3","author":"Graci","year":"2005","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0040|cit40","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780192632340.001.0001","volume-title":"Oxford Textbook of Clinical Pharmacology and Drug Therapy","author":"Grahame-Smith","year":"2002"},{"issue":"9","key":"10.1002\/14651858.CD011108.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/cncr.25761","article-title":"Cancer-related chronic pain: examining quality of life in diverse cancer survivors","volume":"117","author":"Green","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ypmed.2019.02.018","article-title":"Prescription opioid misuse among middle-aged and older adults in the United States, 2015-2016","volume":"121","author":"Han","year":"2019","journal-title":"Preventive Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","article-title":"Morphine and alternative opioids in cancer pain: the EAPC recommendations","volume":"84","author":"Hanks","year":"2001","journal-title":"British Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010756.pub2","article-title":"Corticosteroids for the management of cancer-related pain in adults","author":"Haywood","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019 Available from training.cochrane.org\/handbook\/archive\/v6","DOI":"10.1002\/9781119536604"},{"issue":"9","key":"10.1002\/14651858.CD011108.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","article-title":"The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD011108.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/0269216311406313","article-title":"A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project","volume":"25","author":"King","year":"2011","journal-title":"Palliative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0269216311401948","article-title":"A systematic review of oxycodone in the management of cancer pain","volume":"25","author":"King","year":"2011","journal-title":"Palliative Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011108.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/jpm.2006.9.437","article-title":"Sleep disturbance in supportive care of cancer: a review","volume":"9","author":"Kvale","year":"2006","journal-title":"Journal of Palliative Medicine"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ejca.2008.03.022","article-title":"Management of cancer pain: basic principles and neuropathic cancer pain","volume":"44","author":"Laird","year":"2008","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0053|cit53","volume-title":"Palliative Care: Transforming the Care of Serious Illness","author":"Meier","year":"2010"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00520-004-0623-4","article-title":"Sleep disorders in advanced cancer patients: prevalence and factors associated","volume":"12","author":"Mercadante","year":"2004","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD011108.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0885-3924(99)00036-6","article-title":"Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial","volume":"18","author":"Miller","year":"1999","journal-title":"Journal of Pain and Symptom Management"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/anae.12148","article-title":"Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome","volume":"68","author":"Moore","year":"2013","journal-title":"Anaesthesia"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2005.01.007","article-title":"Hydromorphone","volume":"29","author":"Murray","year":"2005","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0059|cit59","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis. Version 1.2021 www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1415"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0885-3924(02)00390-1","article-title":"Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain","volume":"23","author":"Palangio","year":"2002","journal-title":"Journal of Pain and Symptom Management"},{"issue":"5","key":"10.1002\/14651858.CD011108.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/0269216310387962","article-title":"The role of hydromorphone in cancer pain treatment: a systematic review","volume":"25","author":"Pigni","year":"2011","journal-title":"Palliative Medicine"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"issue":"9784","key":"10.1002\/14651858.CD011108.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","article-title":"Treatment of cancer pain","volume":"377","author":"Portenoy","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011108.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0885-3924(02)00643-7","article-title":"A systematic review of hydromorphone in acute and chronic pain","volume":"25","author":"Quigley","year":"2003","journal-title":"Journal of Pain and Symptom Management"},{"issue":"3","key":"10.1002\/14651858.CD011108.pub3-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004847.pub2","article-title":"Opioid switching to improve pain relief and drug tolerability","author":"Quigley","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0066|cit66","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 2014"},{"issue":"4","key":"10.1002\/14651858.CD011108.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1188\/11.CJON.374-379","article-title":"Oncology pain and complementary therapy","volume":"15","author":"Running","year":"2011","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"2","key":"10.1002\/14651858.CD011108.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s005200000183","article-title":"Hydromorphone: pharmacology and clinical applications in cancer patients","volume":"9","author":"Sarhill","year":"2001","journal-title":"Supportive Care Cancer"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-7-2","article-title":"Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food","volume":"7","author":"Sathyan","year":"2007","journal-title":"BMC Clinical Pharmacology"},{"issue":"9","key":"10.1002\/14651858.CD011108.pub3-BIB0070|cit70","first-page":"135","article-title":"Opioid Rotation in Cancer Pain Treatment: A Systematic Review.","volume":"115","author":"Schuster","year":"2018","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0071|cit71","volume-title":"Pain Relief in Advanced Cancer","author":"Twycross","year":"1994"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00000542-198809000-00029","article-title":"Patient controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone","volume":"69","author":"Urquhart","year":"1988","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1002\/14651858.CD011108.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"Van den Beuken-van Everdingen","year":"2007","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD011108.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"Van den Beuken-Van","year":"2016","journal-title":"Journal of Pain and Symptom Management"},{"issue":"1-3","key":"10.1002\/14651858.CD011108.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0168-3659(01)00550-8","article-title":"Formulation aspects in the development of osmotically controlled oral drug delivery systems","volume":"79","author":"Verma","year":"2002","journal-title":"Journal of Controlled Release"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0076|cit76","volume-title":"Cancer Pain Relief","author":"World Health Organization","year":"1986"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0077|cit77","unstructured":"World Health Organization WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, 2019 www.who.int\/publications\/i\/item\/9789241550390"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0078|cit78","volume-title":"International Classification of Diseases for Mortality and Morbidity Statistics","year":"2019"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003868.pub3","article-title":"Oral morphine for cancer pain","author":"Wiffen","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012592.pub2","article-title":"Opioids for cancer pain - an overview of Cochrane reviews","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD011108.pub3-BIB0081|cit81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012637.pub2","article-title":"Oral paracetamol (acetaminophen) for cancer pain","author":"Wiffen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011108.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths - United States, 2017-2018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"3-4","key":"10.1002\/14651858.CD011108.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3121\/cmr.2008.813","article-title":"Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain","volume":"6","author":"Yakovlev","year":"2008","journal-title":"Clinical Medicine & Research"},{"issue":"10","key":"10.1002\/14651858.CD011108.pub3-BIB0084|cit84","first-page":"DOI: 10.1002\/14","article-title":"Hydromorphone for cancer pain","volume":"CD01110","author":"Bao","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD011108.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003447.pub2","article-title":"Hydromorphone for acute and chronic pain","author":"Quigley","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T23:09:35Z","timestamp":1699312175000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011108.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":85,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011108.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}